Neurocrine Biosciences (NASDAQ:NBIX) had its price objective hoisted by stock analysts at Deutsche Bank to $97.00 in a note issued to investors on Wednesday. The brokerage currently has a “buy” rating on the stock. Deutsche Bank’s price target would suggest a potential upside of 13.61% from the stock’s previous close.
Several other brokerages have also commented on NBIX. Barclays restated an “overweight” rating and set a $100.00 price target on shares of Neurocrine Biosciences in a research note on Wednesday. Oppenheimer set a $100.00 price target on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a research note on Wednesday. JPMorgan Chase & Co. increased their price target on shares of Neurocrine Biosciences from $79.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday. BidaskClub upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, January 31st. Finally, Citigroup restated a “buy” rating and set a $79.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. One equities research analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $89.53.
Neurocrine Biosciences (NBIX) traded up $1.69 during trading on Wednesday, reaching $85.38. 1,678,433 shares of the company’s stock traded hands, compared to its average volume of 1,030,000. The firm has a market cap of $7,560.00, a price-to-earnings ratio of -38.46, a PEG ratio of 6.41 and a beta of 0.26. The company has a current ratio of 14.38, a quick ratio of 14.37 and a debt-to-equity ratio of 1.05. Neurocrine Biosciences has a 1 year low of $39.21 and a 1 year high of $91.82.
In related news, insider Darin Lippoldt sold 6,279 shares of the company’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $75.04, for a total transaction of $471,176.16. Following the completion of the sale, the insider now directly owns 19,436 shares of the company’s stock, valued at approximately $1,458,477.44. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Kevin Charles Gorman sold 105,983 shares of the company’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $80.25, for a total transaction of $8,505,135.75. Following the sale, the chief executive officer now directly owns 339,482 shares of the company’s stock, valued at $27,243,430.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 337,950 shares of company stock valued at $26,613,876. 4.80% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. TIAA CREF Investment Management LLC boosted its holdings in shares of Neurocrine Biosciences by 14.5% during the 4th quarter. TIAA CREF Investment Management LLC now owns 352,116 shares of the company’s stock worth $27,321,000 after buying an additional 44,642 shares during the period. Teachers Advisors LLC boosted its holdings in shares of Neurocrine Biosciences by 94.9% during the 4th quarter. Teachers Advisors LLC now owns 193,395 shares of the company’s stock worth $15,006,000 after buying an additional 94,154 shares during the period. Hanseatic Management Services Inc. bought a new stake in shares of Neurocrine Biosciences during the 4th quarter worth $965,000. Paloma Partners Management Co boosted its holdings in shares of Neurocrine Biosciences by 33.4% during the 4th quarter. Paloma Partners Management Co now owns 34,145 shares of the company’s stock worth $2,649,000 after buying an additional 8,557 shares during the period. Finally, Perceptive Advisors LLC boosted its holdings in shares of Neurocrine Biosciences by 7.5% during the 4th quarter. Perceptive Advisors LLC now owns 5,151,589 shares of the company’s stock worth $399,712,000 after buying an additional 360,000 shares during the period.
TRADEMARK VIOLATION NOTICE: “Neurocrine Biosciences (NBIX) Given New $97.00 Price Target at Deutsche Bank” was first posted by American Banking News and is owned by of American Banking News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/02/14/neurocrine-biosciences-nbix-given-new-97-00-price-target-at-deutsche-bank.html.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.